Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients

• Published in: European journal of cancer (1990) Vol. 72; pp. 54 - 61
• Main Authors: Carton, E., Noe, G., Huillard, O., Golmard, L., Giroux, J., Cessot, A., Saidu, N.E.B., Peyromaure, M., Zerbib, M., Narjoz, C., Guibourdenche, J., Thomas, A., Vidal, M., Goldwasser, F., Blanchet, B., Alexandre, J.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.02.2017; Elsevier Science Ltd
• Subjects: Abiraterone acetate; Aged; Aged, 80 and over; Androgen Antagonists - blood; Androgen Antagonists - pharmacokinetics; Androgen Antagonists - therapeutic use; Androstenes - blood; Androstenes - pharmacokinetics; Androstenes - therapeutic use; Antigens; Cancer; Castration; Chromatography; Confidence intervals; Disease-Free Survival; Drug monitoring; Exposure; Fluorescence; Hematology, Oncology and Palliative Medicine; Humans; Kaplan-Meier Estimate; Liquid chromatography; Logistic Models; Male; Metastases; Metastasis; Metastatic castration-resistant prostate carcinoma; Multivariate analysis; Patients; Pharmacodynamics; Pharmacology; Prospective Studies; Prostate cancer; Prostate-specific antigen; Prostate-Specific Antigen - blood; Prostatic Neoplasms, Castration-Resistant - blood; Prostatic Neoplasms, Castration-Resistant - drug therapy; PSA response; Trough concentration; Drug monitoring; Trough concentration; Metastatic castration-resistant prostate carcinoma; Abiraterone acetate; PSA response

Abiraterone (ABI) is a major oral agent for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients but its systemic exposure is subject to a large inter-individual variability. We aimed to explore the relationship between ABI trough plasma concentration and prostate-specif...